SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

This study looks at the long-term safety of a drug called litifilimab for adults with active systemic lupus erythematosus (SLE). Participants, who have already completed a previous study, will receive injections of litifilimab every 4 weeks for up to 156 weeks while continuing th…

This early-stage study tests a new drug called SG301, given as a shot under the skin, to see if it is safe for people with systemic lupus erythematosus (SLE). The study first gives a single dose to healthy volunteers, then multiple doses to lupus patients. About 48 people will ta…

This study was designed to test a new treatment combining a patient's own engineered immune cells (CLBR001) with a targeted antibody (SWI019) for people with lupus, scleroderma, or inflammatory myositis. Participants would have received one infusion of cells followed by cycles of…

This early study tests a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. Six adults whose lupus remains active despite standard medications will receive these specially engineered immune cells. The main goals are…

This early-stage study tests a new drug called KK4277 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body. The study does not aim to cure lupus, bu…

This early-phase study tests a new treatment called Prula-cel for people with certain autoimmune diseases like lupus and scleroderma. Prula-cel uses specially engineered immune cells from a healthy donor to target and attack faulty immune cells that cause disease. The main goals …